Relevant Applications of Generative Adversarial Networks in Drug Design and Discovery: Molecular De Novo Design, Dimensionality Reduction, and De Novo Peptide and Protein Design

Abstract

A growing body of evidence now suggests that artificial intelligence and machine learning techniques can serve as an indispensable foundation for the process of drug design and discovery. In light of latest advancements in computing technologies, deep learning algorithms are being created during the development of clinically useful drugs for treatment of a number of diseases. In this review, we focus on the latest developments for three particular arenas in drug design and discovery research using deep learning approaches, such as generative adversarial network (GAN) frameworks. Firstly, we review drug design and discovery studies that leverage various GAN techniques to assess one main application such as molecular de novo design in drug design and discovery. In addition, we describe various GAN models to fulfill the dimension reduction task of single-cell data in the preclinical stage of the drug development pipeline. Furthermore, we depict several studies in de novo peptide and protein design using GAN frameworks. Moreover, we outline the limitations in regard to the previous drug design and discovery studies using GAN models. Finally, we present a discussion of directions and challenges for future research.

Prediction of Probable Major Depressive Disorder in the Taiwan Biobank: An Integrated Machine Learning and Genome-Wide Analysis Approach

“…It is hypothesized that using the whole dataset without a certain timeframe in the cross-validation procedure might disguise any cohort-specific effects on how MDD might manifest in the patients as time passed [ 64 , 65 , 66 ]. On the other hand, the main advantage of machine learning methods over deep learning approaches is that extensive computing resources (i.e., general-purpose computing on graphics processing units), which are normally utilized in deep learning algorithms, are in general not required for implementing machine learning models [ 67 , 68 ].…”

Evolving scenario of big data and Artificial Intelligence (AI) in drug discovery

“…The iterative procedure of optimizing fake data to resemble the real data by the generative network and its discrimination by the discriminative network continues until local Nash equilibrium is attained, at which there is no further reduction in the cost of both generator and the discriminator [ 89 ]. Many novel applications of GANs in cheminformatics and computer-aided drug design have emerged recently [ 90 ]. The modification of GANs such as conditional GAN [ 91 ] and Wasserstein GAN [ 92 ] have proved to be very useful in various tasks such as novel molecule design (Fig.…”

Deep learning and generative methods in cheminformatics and chemical biology: navigating small molecule space intelligently

“…Virtually all remedies are designed to minimise this and thus to improve generalisation by 'sparsifying' or regularising the trained network. Some such methods include the use of 'decoys' (especially generative adversarial networks [53,124,125]), the use of heavy pruning during training, especially 'dropout' [126], training in small batches [127], using ensembles of the same network [128], and the addition of noise (even 'randomised' SMILES strings [71,117]) to the inputs. It seems that in some cases the values of the hyperparameters are critical, and they interact with each other in complex and hard-to-predict ways (and they may also be optimised using evolutionary algorithms).…”